| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cca68e4a4a24ac20289ea87a1ae6e9c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba3f70d4bcad1958ae8868ddab079b8f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2017-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3713faea8ab632c5a03466c0c5db81c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ceeb2b8113fd7d580eeb293c7395995
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b98859557d0e3b64b87add3ee9f5336 |
| publicationDate |
2018-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018001874-A1 |
| titleOfInvention |
Fusion protein for use in the treatment of hvg disease |
| abstract |
The invention provides a fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host´s immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02or SLA-01*0401in a recipient patient who is negative for HLA-A*02or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02or SLA-01*0401. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3733697-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020201230-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112004924-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023180690-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020221902-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023111594-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3714944-A1 |
| priorityDate |
2016-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |